This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Motzer, R. J. Articles by Metz, E. M. Search for Related Content PubMed PubMed Citation Articles by Motzer, R. J. Articles by Metz, E. M. Social Bookmarking                            What's this?

Effect of Cytokine Therapy on Survival for Patients With Advanced Renal Cell Carcinoma

From the Genitourinary Oncology Service, Division of Solid Tumor Oncology, and Departments of Medicine, Biostatistics and Epidemiology, and Urology, Memorial Sloan-Kettering Cancer Center, and Department of Medicine, Cornell University Medical College, New York, NY.

Address reprint requests to Robert J. Motzer, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.

PURPOSE: To evaluate the relationship between treatment with cytokine therapy and survival, investigate the effect of nephrectomy on survival, and identify long-term survivors among a cohort of 670 patients with advanced renal cell carcinoma (RCC).

PATIENTS AND METHODS: A total of 670 patients with advanced RCC treated on 24 clinical trials of systemic chemotherapy or cytokine therapy were the subjects of this retrospective analysis. Treatment was categorized as cytokine (containing interferon alfa and/or interleukin-2) in 396 patients (59%) and as chemotherapy (cytotoxic or hormonal therapy) in 274 (41%). Among the 670 patients, those with survival times of greater than 5 years were identified as long-term survivors.

RESULTS: Patients treated with cytokine therapy had a longer survival time than did those treated with chemotherapy, regardless of the year of treatment or risk category based on pretreatment features. The median survival times for favorable-, intermediate-, and poor-risk patients were 27, 12, and 6 months for those treated with cytokines and 15, 7, and 3 months for those treated with chemotherapy, respectively. The magnitude of difference in median survival was greater in the favorable- and intermediate-risk groups. The median survival time was less than 6 months in the poor-risk group for both treatment programs. Median survival time was 14 months among patients with prior nephrectomy plus time from diagnosis to treatment greater than 1 year versus 8 months among those with time from diagnosis to treatment less than 1 year, regardless of pretreatment nephrectomy status. Thirty patients (4.5%) among the 670 patients were identified as long-term survivors; 12 were free of disease after nephrectomy and treatment with interferon alfa, interleukin-2, or surgical resection of metastasis.

CONCLUSION: The low proportion of patients with advanced RCC who achieve long-term survival emphasizes the need for clinical investigation to identify more effective therapy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. B. Dorff, A. Goldkorn, and D. I. Quinn Review: Targeted therapy in renal cancer Therapeutic Advances in Medical Oncology, November 1, 2009; 1(3): 183 - 205. [Abstract] [PDF]

				S. A.J. VAZIRI, D. R. GRABOWSKI, J. HILL, L. R. RYBICKI, R. BURK, R. M. BUKOWSKI, M. K. GANAPATHI, and R. GANAPATHI Inhibition of Proteasome Activity by Bortezomib in Renal Cancer Cells Is p53 Dependent and VHL Independent Anticancer Res, August 1, 2009; 29(8): 2961 - 2969. [Abstract] [Full Text] [PDF]

				T. Schwaab, A. Schwarzer, B. Wolf, T. S. Crocenzi, J. D. Seigne, N. A. Crosby, B. F. Cole, J. L. Fisher, J. C. Uhlenhake, D. Mellinger, et al. Clinical and Immunologic Effects of Intranodal Autologous Tumor Lysate-Dendritic Cell Vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a Therapy in Metastatic Renal Cell Carcinoma Patients Clin. Cancer Res., August 1, 2009; 15(15): 4986 - 4992. [Abstract] [Full Text] [PDF]

				B. Melichar, P. Koralewski, A. Ravaud, A. Pluzanska, S. Bracarda, C. Szczylik, C. Chevreau, M. Filipek, R. Delva, E. Sevin, et al. First-line bevacizumab combined with reduced dose interferon-{alpha}2a is active in patients with metastatic renal cell carcinoma Ann. Onc., August 1, 2008; 19(8): 1470 - 1476. [Abstract] [Full Text] [PDF]

				L. Q.M. Chow and S. G. Eckhardt Sunitinib: From Rational Design to Clinical Efficacy J. Clin. Oncol., March 1, 2007; 25(7): 884 - 896. [Abstract] [Full Text] [PDF]

				R. J. Motzer and R. M. Bukowski Targeted Therapy for Metastatic Renal Cell Carcinoma J. Clin. Oncol., December 10, 2006; 24(35): 5601 - 5608. [Abstract] [Full Text] [PDF]

				L. A. Fumagalli and F. Brivio Immunotherapy and Prognostic Factors J. Clin. Oncol., September 1, 2006; 24(25): 4218 - 4219. [Full Text] [PDF]

				F. Donskov and H. von der Maase Impact of Immune Parameters on Long-Term Survival in Metastatic Renal Cell Carcinoma J. Clin. Oncol., May 1, 2006; 24(13): 1997 - 2005. [Abstract] [Full Text] [PDF]

				N. Aass, P. H.M. De Mulder, G. H.J. Mickisch, P. Mulders, A. T. van Oosterom, H. van Poppel, S. D. Fossa, L. de Prijck, and R. J. Sylvester Randomized Phase II/III Trial of Interferon Alfa-2a With and Without 13-cis-Retinoic Acid in Patients With Progressive Metastatic Renal Cell Carcinoma: The European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951) J. Clin. Oncol., June 20, 2005; 23(18): 4172 - 4178. [Abstract] [Full Text] [PDF]

				R. J. Amato Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens Ann. Onc., January 1, 2005; 16(1): 7 - 15. [Abstract] [Full Text] [PDF]

				R. J. Motzer, J. Bacik, and M. Mazumdar Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma: Memorial Sloan-Kettering Cancer Center Experience Clin. Cancer Res., September 15, 2004; 10(18): 6302S - 6303S. [Abstract] [Full Text] [PDF]

				M.-H. Tan, C. G. Rogers, J. T. Cooper, J. A. Ditlev, T. J. Maatman, X. Yang, K. A. Furge, and B. T. Teh Gene Expression Profiling of Renal Cell Carcinoma Clin. Cancer Res., September 15, 2004; 10(18): 6315S - 6321S. [Abstract] [Full Text] [PDF]

				S. Negrier, D. Perol, C. Menetrier-Caux, B. Escudier, M. Pallardy, A. Ravaud, J.-Y. Douillard, C. Chevreau, C. Lasset, and J.-Y. Blay Interleukin-6, Interleukin-10, and Vascular Endothelial Growth Factor in Metastatic Renal Cell Carcinoma: Prognostic Value of Interleukin-6--From the Groupe Francais d'Immunotherapie J. Clin. Oncol., June 15, 2004; 22(12): 2371 - 2378. [Abstract] [Full Text] [PDF]

				H. X. Chen Expanding the Clinical Development of Bevacizumab Oncologist, June 1, 2004; 9(suppl_1): 27 - 35. [Abstract] [Full Text] [PDF]

				S. Negrier Better Survival With Interleukin-2-Based Regimens? Possibly Only in Highly Selected Patients J. Clin. Oncol., April 1, 2004; 22(7): 1174 - 1176. [Full Text] [PDF]

				I. Y. Kim, D.-H. Lee, D. K. Lee, B. C. Kim, H. T. Kim, F. S. Leach, W. M. Linehan, R. A. Morton, and S. J. Kim Decreased Expression of Bone Morphogenetic Protein (BMP) Receptor Type II Correlates with Insensitivity to BMP-6 in Human Renal Cell Carcinoma Cells Clin. Cancer Res., December 1, 2003; 9(16): 6046 - 6051. [Abstract] [Full Text] [PDF]

				R. J. Motzer Renal Cell Carcinoma: A Priority Malignancy for Development and Study of Novel Therapies J. Clin. Oncol., April 1, 2003; 21(7): 1193 - 1194. [Full Text] [PDF]

				P. Indolfi, M. Terenziani, F. Casale, M. Carli, G. Bisogno, A. Schiavetti, A. Mancini, R. Rondelli, A. Pession, A. Jenkner, et al. Renal Cell Carcinoma in Children: A Clinicopathologic Study J. Clin. Oncol., February 1, 2003; 21(3): 530 - 535. [Abstract] [Full Text] [PDF]

				S. Negrier, B. Escudier, F. Gomez, J.-Y. Douillard, A. Ravaud, C. Chevreau, M. Buclon, D. Perol, and C. Lasset Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie Ann. Onc., September 1, 2002; 13(9): 1460 - 1468. [Abstract] [Full Text] [PDF]

				S. Coral, L. Sigalotti, M. Altomonte, A. Engelsberg, F. Colizzi, I. Cattarossi, E. Maraskovsky, E. Jager, B. Seliger, and M. Maio 5-aza-2'-Deoxycytidine-induced Expression of Functional Cancer Testis Antigens in Human Renal Cell Carcinoma: Immunotherapeutic Implications Clin. Cancer Res., August 1, 2002; 8(8): 2690 - 2695. [Abstract] [Full Text] [PDF]

				R. J. Motzer, J. Bacik, B. A. Murphy, P. Russo, and M. Mazumdar Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma J. Clin. Oncol., January 1, 2002; 20(1): 289 - 296. [Abstract] [Full Text] [PDF]

				R. J. Motzer, B. A. Murphy, J. Bacik, L. H. Schwartz, D. M. Nanus, T. Mariani, P. Loehrer, G. Wilding, D. L. Fairclough, D. Cella, et al. Phase III Trial of Interferon Alfa-2a With or Without 13-cis-Retinoic Acid for Patients With Advanced Renal Cell Carcinoma J. Clin. Oncol., August 16, 2000; 18(16): 2972 - 2980. [Abstract] [Full Text] [PDF]